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The use of percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) has successfully reduced the incidence of associated mortality and/or morbidity. However, despite widespread use of PCI, there has been an increase in the prevalence of ischaemic heart failure, which is mainly attributable to the fact that this treatment has not been as successful as expected in limiting the size of infarcts. Because reducing the infarct size is essential to decrease the development of heart failure, PCI alone is not sufficient to reduce the incidence of ischaemic heart failure following AMI. To overcome this challenge, many researchers have investigated the major causes of ischaemia and reperfusion injury and methods to attenuate the damage caused by them. 1 Moreover, they used mice lacking TPC1 and found that these mice were protected against cardiac ischaemia and reperfusion. Taken together, the most important and novel points of the present study are considered to be the following: (i) the authors clarified the involvement of NAADP signalling and thus the increase in [Ca 2+ ] c via lysosomes in the reperfusion injury of the heart and (ii) they developed Ned-K as an NAADP antagonist and showed Ned-K-mediated cardioprotection via inhibition of Ca 2+ overload, Ca 2+ oscillation and consequently mPTP opening, in a similar manner to cyclosporine. Based on the present findings, a diagram on how Ca 2+ overload occurs and causes cardiovascular injury can be proposed (Figure 1 ). This study is particularly important for guiding future research to target lysosomes as a contributor to Ca 2+ homeostasis, a pathway that has been ignored for a long time because lysosomes are believed to play a role as scavengers of intracellular substances such as lipids, amino acids, and proteins. The endoplasmic reticulum (ER) and SR are also opening. ER, endoplasmic reticulum; SR, sarcoplasmic reticulum; IP3, 1,4,5-trisphosphate; IP3R, the receptor for IP3; RyR, ryanodine receptor; cADPR, cyclic ADP-ribose; NAADP, nicotinic acid adenine dinucleotide phosphate; TPC, two-pore channels; ROS, reactive oxygen spices; Mt, mitochondrion; mPTP, mitochondrial permeability transition pore.
Cellular mechanisms underlying reperfusion injury
Editorial scavengers of proteins; however, they are predominantly considered Ca 2+ -handling organelles. The present study demonstrates the importance of lysosomes for reperfusion injury rather than ER/SR in the myocardium.
Unresolved issues and future perspectives
The present work has some limitations and issues. First, the reason for the differences between the infarct size-limiting effects of Ned-19 and Ned-K was not examined. Second, before bringing Ned-K to the clinic as a drug-targeting ischaemia and reperfusion injury, the safety issues associated with NED-K use remain to be explored. In addition, the effects of Ned-K on haemodynamic parameters, such as blood pressure and heart rate, need to be elucidated. Such measurements are necessary to determine whether the compound is safe for future clinical use as well as to know its effects on haemodynamic parameters that may alter the infarct size even in the absence of direct cardioprotective effects of Ned-K. Heart rate and systemic blood pressure are known to substantially change the infarct size.
Third, the authors should still clarify the non-specific effects of Ned-K because the chemical compound may have other effects that influence infarct size limitation.
Fourth, the interaction between lysosomes and SR for the regulation of [Ca 2+ ] c and Ca 2+ overload is still to be demonstrated and the quantitative contribution of lysosomes and SR to Ca 2+ overload should be clarified in reperfused hearts. Finally, although cyclosporine blocks mPTP, cyclosporine did not limit the size of infarcts in a recently conducted large-scale human clinical trial, 8 suggesting that mPTPs, possible end-effectors of Ned-K, may not be cardioprotective for patients with AMI. These issues should be seriously considered in future studies. Nonetheless, the study is a major step forward in demonstrating the importance of lysosomes in Ca 2+ homeostasis and the potential of Ned-K as a drug targeting ischaemic heart diseases. Importantly, Davidson et al. 5 demonstrate that targeting this pathway at the time of reperfusion (and not only in pre-treatment) can reduce perfusion injury, showing the potential for clinical application.
